Mireca Medicines

Mireca Medicines is a private, preclinical-stage biotechnology company based in Munich (with R&D in Tübingen), Germany, developing novel cGMP-analog therapeutics. Its lead program targets the inhibition of protein kinase G (PKG) to provide neuroprotection in a broad range of inherited retinal diseases, a strategy supported by positive preclinical data. The company is built on foundational science from a long-running European consortium and is led by a team with entrepreneurial and ophthalmology research expertise. Mireca's approach addresses a common disease mechanism across many genetic mutations, positioning it to potentially treat a significant orphan disease population.

Proprietary cyclic guanosine monophosphate (cGMP)-analogs and drug delivery technologies designed to correct dysregulated cGMP signaling, specifically targeting overactivation of protein kinase G (PKG) to provide neuroprotection.

Mireca competes in the inherited retinal disease space against gene therapy companies (e.g., Spark Therapeutics) targeting specific mutations and other neuroprotective approaches. Its key differentiation is a small molecule, mutation-agnostic strategy aimed at slowing progression across many genetic forms, contrasting with high-cost, mutation-specific gene replacement therapies.